Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 715-716

  Pardanani, A ^a   Brown, P ^a   Neben Wittich, M ^a   Tobin, R ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b Rocky Mountain Oncology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CASE REPORT; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PRIMARY MYELOFIBROSIS; RADIATION DOSE; RADIATION RESPONSE; REMISSION; SPLEEN; SPLENOMEGALY;

ADULT; FEMALE; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SPLEEN; SPLENOMEGALY;

EID: 77956463371     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21799     Document Type: Article

References (8)

1. Jyothirmayi R, Coltart S. An audit of the indications for and techniques of palliative splenic radiotherapy in the UK. Clin Oncol (R Coll Radiol) 2005;17:192-194.
2. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003;78:1223-1233.
3. Weinmann M, Becker G, Einsele H, Bamberg M. Clinical indications and biological mechanisms of splenic irradiation in chronic leukaemias and myeloproliferative disorders. Radiother Oncol 2001;58:235-246.
4. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103:505-511.
5. Tefferi A, Jimenez T, Gray LA, et al. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol 2001;66:37-42.
6. Riesterer O, Gmur J, Lutolf U. Repeated and preemptive palliative radiotherapy of symptomatic hepatomegaly in a patient with advanced myelofibrosis. Onkologie 2008;31:325-327.
7. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 2009;27:5587-5593.
8. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726-2732.